ArticleCadernos de saude publica2025
[Cervical cancer screening in Brazil: a coverage analysis using the Brazilian Cancer Information System].
Article in Cadernos de saude publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Past, present, and future of screening for cervical cancer in Brazil: lessons learned?Cadernos de saude publica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to analyze the coverage of cervical cancer screening in Brazil and its Federative Units (UF, acronym in Portuguese) using secondary data from the Brazilian Cancer Information System (SISCAN, acronym in Portuguese), and to compare it with the index of exam rate in females, classically used as a proxy for coverage, and to estimate the possible coverage, if the national guidelines recommended by the Brazilian Ministry of Health were properly followed by health professionals. Cytopathological tests performed between 2021 and 2023 in women up to 64 years old, registered in SISCAN and in the Outpatient Information System of the SUS (SIA/SUS, acronym in Portuguese), were selected. Coverage and ratio indicators were calculated by UF of residence. The estimated screening coverage was estimated by adding up all the tests performed in the period in women up to 64 years old and dividing by the target population (25-64 years). The estimated screening coverage for Brazil was 35.6%, which is lower than the values of the index of exam rate (47.4 and 47.8 per 100 women according to SISCAN and SIA/SUS, respectively). It was found that by directing the tests to the appropriate age group and periodicity, coverage could reach 53.9% in Brazil and exceed 70% in Espírito Santo, Paraná and Santa Catarina. It was concluded that the rate index overestimates coverage by approximately 35% and that screening coverage is far below the 70% recommended by the World Health Organization. However, the sensitization of professionals regarding the guidelines of the Brazilian Ministry of Health can change this scenario, optimizing resources and generating a positive impact on cervical cancer incidence and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.